Author:
Vasil’eva Olga A.,Prokhorenko T. S.,Kolobovnikova Y. V.,Poletika V. S.,Urazova O. I.,Kononova T. E.,Churina E. G.,Reynhardt G. V.,Kurnosenko A. V.
Abstract
Aim of the study. To investigate the effect of recombinant galectin-3 on the cytokines secretion of various subpopulations of helper-lymphocytes (Th1, Th2, Th17, Treg) in culture in vitro. Material and methods. The material for the study was peripheral blood from healthy people (n=17), from which lymphocytes were isolated by gradient centrifugation. Lymphocytes were cultured for 72 hours in a CO2-incubator with recombinant galectin-3 and activating antibodies (antiCD3/antiCD28). The concentration of cytokines (IL-10, IL-13, IL-17A, IL-22, IFN, TNF, TGF1) in the supernatants of lymphocyte cultures was determined by enzyme immunoassay. Results. Recombinant galectin-3 in vitro enhanced the secretion of IL-17A, IL-22 by lymphocytes, acting at a dose of 0.5 g/ml; IL-13, TNF and IFN at doses of 0.5 g/ml and 1 /ml (more pronounced when acting at a dose of 0.5 g/ml) and inhibited the production of IL-17, IL-22 at a dose of 1 g/ml and IL-10, TGF1 when testing both concentrations. Conclusion: Galectin-3 has a dose-dependent modulating effect on the cytokine-producing function of healthy donors lymphocytes in vitro. Functional imbalance in blood lymphocytes under the action of recombinant galectin-3 is manifested by induction of pro-inflammatory (IFN, IL-17, IL-22, TNF) and anti-inflammatory (interleukin-13) cytokines secretion, against the background of oppression of the suppressor cytokines (IL-10 and TGF1) production. A detailed study of the immunotropic effects of galectin-3 in relation to individual lymphocytes subpopulations is relevant from the view point of development new approaches to the treatment of tumor and autoimmune diseases accompanied by excessive production of this lectin.
Reference15 articles.
1. Полетика В.С., Колобовникова Ю.В., Уразова О.И., Васильева О.А., Дмитриева А.И., Янкович К.И., Новицкий В.В., Рябова Л.М., Грищенко М.Ю. Роль галектина-1, -3 в механизмах дисрегуляции Т-клеточного звена иммунного ответа при раке толстого кишечника // Бюллетень сибирской медицины. – 2020. – Т.19, № 3. – С. 76–82.
2. Симбирцев А.С. Цитокины: классификация и биологические функции // Цитокины и воспаление. – 2004. – № 2. – С. 16-21.
3. Ярилин А.А. Транскрипционные регуляторы дифференцировки Т-хелперов // Иммунология. – 2010. – № 3. – С. 153-168.
4. Chen K. Kolls J.K. Interleukin-17A (IL17A). Gene, 2017, Vol. 30, pp. 8-14.
5. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., Weiner H.L., Kuchroo V.K. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature, 2006, Vol. 441, pp. 235–238.